Nordic Nanovector Announces US Patent Granted Covering the Use of Betalutin® to Sensitise B-Cell Cancer Cells to CD20 Immunotherapy
Oslo, Norway, 5 May 2020 Nordic Nanovector ASA (OSE:) is pleased to announce the grant of a US patent covering the use of Betalutin® ([177]Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estate around the use of Betalutin® in combination with other drugs that target antigens presented on the surface of tumour cells in patients with B-cell malignancies, such as Non-Hodgkin’s Lymphoma (NHL). The company believes that the combination of